Comparative assessment of the absorption of a test formulation of 1 x 10 mg alitretinoin capsule against the innovator 1 x 10 mg alitretinoin capsule conducted under fed conditions in healthy male volunteers.
A single dose, randomized, blinded, pharmacokinetic study of a test formulation of 1 x 10 mg alitretinoin capsule in a 2 way crossover comparison against the innovator 1 x 10 mg alitretinoin capsule conducted under fed conditions in healthy male volunteers.
Zenith Technology Corp Ltd
30 participants
Mar 1, 2018
Interventional
Conditions
Summary
The objective of this study is to evaluate the bioequivalence of the test (new) formulation of 10 mg alitretinoin capsule relative to that of the reference formulation (innovator brand of 10 mg alitreinoin capsule) following oral administration of a single dose of 10 mg in healthy male subjects under fed conditions.
Eligibility
Inclusion Criteria8
- Healthy males
- Aged between 18 and 55 years
- Non-smoker
- BMI greater than or equal to 19 and less than 30 inclusive
- Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- Drug free as determined by urine drug testing
- Able to comply with the study restrictions
- Able to provide written informed consent
Exclusion Criteria11
- Females
- History of recent recurrent attacks of bronchitis, asthma or migraine headaches
- Concomitant drug therapy of any kind
- Received an investigational compound or drug known to induce or inhibit liver enzymes within 60 days of the start of the study
- History of depression or other mental illness, or a history of epilepsy or seizures
- History of conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- History of alcohol or drug abuse or dependency
- Sensitivities to Vitamin A or food such as liver
- Participation in a drug study within 60 days of the start of the study or undertaking to donate blood within 60 days after the completion of the study
- Sensitivities to alitretinoin, its excipients or any other retinoids
- Individuals for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single dose, crossover study design whereby each participant receives the test formulation of alitretinoin, 1 x 10 mg capsule on one occasion and the innovator formulation of alitretinoin, 1 x 10 mg capsule on one occasion with each dose separated by a one week washout period. The intervention for this trial is the test formulation of alitretinoin. No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with each dose). Participants are required not to eat for 10 hours before receiving a standardised high fat content meal and to fast for approximately 4 hours after each dose. Bathroom visits will be supervised to ensure no unauthorized water or food intake and for personal safety. Participants will be confined at the Clinical Site for 12 hours prior to dosing to ensure compliance and for 24 hours after dosing. Participants will be monitored for adverse events throughout the study. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 12 hours prior to dosing. Pre and post study laboratory tests will be completed to assess the health of the participants along with HIV, Hepatitis and drugs of abuse testing. Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure that the medication has been taken as directed.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618000247279